Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

The investment case for Sanofi

Except for a select few, major pharmaceutical shares have performed poorly over the last few years thanks to negative real interest rates (favouring duration), heightened risk of US drug pricing reforms, intensifying competition and many companies facing large patent cliffs over the next decade.

Good Value Briefing | The supply chain crisis

It’s fair to say global supply chains are in a state of chaos. In recent days we’ve seen staggering images of a record-breaking number of ships, carrying hundreds of thousands of containers, anchored off the California coast.

Good Value Briefing | It’s a stock-pickers market

The S&P500 ended August at yet another high, making it seven consecutive months of gains – the longest winning streak since January 2018. This is relatively rare; a winning streak of seven consecutive months or more has occurred just 14 times in the last 60 years.

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X